Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Cisplatin 18pembrolizumab 12Paclitaxel 9Carboplatin 9Radiotherapy 5Gemcitabine 4Fluorodeoxyglucose F18 4Colposcopy 4Brachytherapy 4fludarabine 3durvalumab 3Surveys and Questionnaires 3Radiation 3Flow Cytometry 3Cyclophosphamide 3Biopsy 3Bevacizumab 3toripalimab 2fludarabine phosphate 2atezolizumab 2aldesleukin 2adavosertib 2Zoledronic Acid 2Topotecan 2Nivolumab 2Neoadjuvant Therapy 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Interleukin-2 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Uterine Cervical Neoplasms × MEDI0457 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡